Trial reportBritish journal of clinical pharmacology2019
A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
Trial report in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.British journal of clinical pharmacology · 2019Trial
- Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.Kidney international reports · 2026Review
- Decoding vascular calcification: mechanistic insights and translational strategies.Cellular and molecular life sciences : CMLS · 2026Review
- Ten tips on how to deal with calciphylaxis patients.Clinical kidney journal · 2025Review
- The Relevance of Phytate for the Treatment of Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2024Review
- Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension.EClinicalMedicine · 2024Article
- SNF472: a novel therapeutic agent for vascular calcification and calciphylaxis.Journal of nephrology · 2024Review
- Hexasodium fytate exposure-response correlations in a randomized, placebo-controlled study of patients on dialysis with cardiovascular calcification.Frontiers in pharmacology · 2024Article
- Phytates as a natural source for health promotion: A critical evaluation of clinical trials.Frontiers in chemistry · 2023Review
- New Therapeutics Targeting Arterial Media Calcification: Friend or Foe for Bone Mineralization?Metabolites · 2022Review
- Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.Clinical kidney journal · 2021Article
- A novel assay to measure calcification propensity: from laboratory to humans.Scientific reports · 2020Article
- Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.British journal of pharmacology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.